MX2020005398A - Compuestos para el tratamiento de trastornos neuromusculares. - Google Patents

Compuestos para el tratamiento de trastornos neuromusculares.

Info

Publication number
MX2020005398A
MX2020005398A MX2020005398A MX2020005398A MX2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A MX 2020005398 A MX2020005398 A MX 2020005398A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
neuromuscular disorders
neuromuscular
disorders
Prior art date
Application number
MX2020005398A
Other languages
English (en)
Spanish (es)
Inventor
Martin Broch-Lips
Olesen Claus Elsborg
Pedersen Thomas Holm
Lars J S Knutsen
Nicholas Kelly
Marc Labelle
Nielsen Ole Bækgaard
Rajesh Kumar
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of MX2020005398A publication Critical patent/MX2020005398A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12Acetic acid esters
    • C07C69/14Acetic acid esters of monohydroxylic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • C07C69/736Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020005398A 2017-12-14 2018-12-14 Compuestos para el tratamiento de trastornos neuromusculares. MX2020005398A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598940P 2017-12-14 2017-12-14
EP18151605 2018-01-15
PCT/EP2018/084980 WO2019115777A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (1)

Publication Number Publication Date
MX2020005398A true MX2020005398A (es) 2020-08-17

Family

ID=64661403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005398A MX2020005398A (es) 2017-12-14 2018-12-14 Compuestos para el tratamiento de trastornos neuromusculares.

Country Status (12)

Country Link
EP (1) EP3723745B1 (https=)
JP (1) JP2021506813A (https=)
KR (1) KR20200099146A (https=)
CN (1) CN111587109A (https=)
AU (1) AU2018382597B2 (https=)
CA (1) CA3085226A1 (https=)
IL (1) IL274744B2 (https=)
MX (1) MX2020005398A (https=)
SG (1) SG11202005359TA (https=)
TW (1) TWI794369B (https=)
WO (1) WO2019115777A1 (https=)
ZA (1) ZA202002936B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025637A2 (pt) * 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
WO2024121130A1 (en) 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2024121129A1 (en) * 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases
WO2025196206A1 (en) 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1586463A (en) 1976-08-02 1981-03-18 Shell Int Research Herbicidal compositions
KR100552133B1 (ko) * 2002-06-26 2006-02-14 한국화학연구원 광학활성 (r)-아릴옥시 프로피온산 에스터 유도체의제조방법
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
MX389242B (es) * 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TW201720437A (zh) * 2015-10-29 2017-06-16 東北泰克諾亞奇股份有限公司 肌萎縮性疾病治療劑

Also Published As

Publication number Publication date
KR20200099146A (ko) 2020-08-21
CN111587109A (zh) 2020-08-25
IL274744B2 (en) 2023-02-01
IL274744B (en) 2022-10-01
TWI794369B (zh) 2023-03-01
EP3723745B1 (en) 2024-06-19
SG11202005359TA (en) 2020-07-29
CA3085226A1 (en) 2019-06-20
AU2018382597A1 (en) 2020-07-02
EP3723745A1 (en) 2020-10-21
ZA202002936B (en) 2024-11-27
JP2021506813A (ja) 2021-02-22
IL274744A (en) 2020-07-30
AU2018382597B2 (en) 2024-04-04
TW201938525A (zh) 2019-10-01
EP3723745C0 (en) 2024-06-19
WO2019115777A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2020005398A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
CL2017002223A1 (es) Métodos para el tratamiento de trastornos del movimiento involuntario anormal
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
NI201800020A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
UY36348A (es) Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2020005471A (es) Compuestos para el tratamiento de trastornos neuromusculares.
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos